![Regioselektivnost' reaktsii SEAR 8-khlor-3,4-digdro-1H-[1,4]oksazino[4,3-a]benzimidazola](/upload/12631c5e396938a702bdd516ae8c4208/issues/cover/bce0ecb87675e8be5c4439151407007b.png)
P.G. Demidov Yaroslavl State University
Yaroslavl, Yaroslavl, Russian Federation
from 01.01.2025 until now
P.G. Demidov Yaroslavl State University (Student)
Yaroslavl, Yaroslavl, Russian Federation
P.G. Demidov Yaroslavl State University (Associate Professor)
Yaroslavl, Yaroslavl, Russian Federation
P.G. Demidov Yaroslavl State University
Yaroslavl, Yaroslavl, Russian Federation
Yaroslavl, Yaroslavl, Russian Federation
S cel'yu effektivnoy funkcionalizacii bifarmakofornoy molekuly 8-hlor-3,4-digidro-1H-[1,4]oksazino[4,3-a]benzimidazola v reakciyah elektrofil'nogo nitrovaniya i galogenirovaniya izucheno vliyanie temperatury processa i vremeni vneseniya elektrofil'nogo agenta na regioselektivnost' reakcii SEAr. V hode dannyh reakciy proishodilo obrazovanie dvuh izomernyh 7- i 9-zameschennyh produktov. V bol'shem kolichestve obrazovyvalsya 7-R-8-hlor-3,4-digidro-1N-[1,4]oksazino[4,3-a]benzimidazol. Umen'shenie temperatury reakcii i koncentracii elektrofil'nogo agenta v reakcionnoy masse uvelichivali selektivnost' processa obrazovaniya dannogo izomera.
Bifarmakofornye molekuly, kondensirovannye proizvodnye benzimidazola, morfolinovyy cikl, regioselektivnost', nitrovanie, galogenirovanie
1. Tevyashova A.N., Olsuf'eva E.N., Preobrazhenskaya M.N. Sozdanie antibiotikov dvoynogo deystviya kak put' poiska novyh perspektivnyh lekarstvennyh preparatov. Uspehi himii, 2015, 84(1), 61-97. doi.org/10.1070/RCR4448. EDN: https://elibrary.ru/TBXVAP
2. Tangadanchu V.K.R., Sui Y.F., Zhou C.H. Isatin-derived azoles as new potential antimicrobial agents: Design, synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2021, 41, 128030. doi.org/10.1016/j.bmcl.2021.128030.
3. Malasala S., Ahmad M.N., Akunuri R., Shukla M., Kaul G., Dasgupta A., Madhavi Y.V., Chopra S., Nanduri S. Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis. Eur. J. Med. Chem., 2021, 212, 112996. https://doi.org/10.1016/j.ejmech.2020.112996. EDN: https://elibrary.ru/NLPVNI
4. Karaca Gençer H., Acar Çevik U., Levent S., Sağlık B., Korkut B.N., Özkay Y., Ilgın S., Öztürk Y. New benzimidazole-1,2,4-triazole hybrid compounds: synthesis, anticandidal activity and cytotoxicity evaluation. Molecules, 2017, 22(4), 507. doi:https://doi.org/10.3390/molecules22040507. EDN: https://elibrary.ru/YYIBJN
5. Aitha S., Thumma V., Ambala S., Matta R., Panga S., Pochampally J. Bis 1, 2, 3‐ triazoles linked deoxybenzoin hybrids as antimicrobial agents: synthesis, in vitro and in silico screening. ChemistrySelect., 2023, 8(13), e202300405. doi:https://doi.org/10.1002/slct.202300405.
6. Aleksandrova Y.R., Nikolaeva N.S., Shagina I.A., Smirnova K.D., Zubishina A.A., Khlopotinin A.I., Fakhrutdinov A.N., Khokhlov A.L., Begunov R.S., Neganova M.E. N-Aryl Benzimidazole and Benzotriazole Derivatives and Their Hybrids as Cytotoxic Agents: Design, Synthesis and Structure–Activity Relationship Studies. Molecules, 2024, 29(22), 5360. https://doi.org/10.3390/molecules29225360 EDN: https://elibrary.ru/GDRPJA
7. Begunov R.S., Egorov D.O., Chetvertakova A.V., Savina L.I., Zubishina A.A. Antibakterial'naya aktivnost' galogen- i nitroproizvodnyh benzimidazola v otnoshenii Bacillus subtilis. Antibiotiki i Himioterapiya, 2023, 68(3-4), 19-24. https://doi.org/10.37489/0235-2990-2023-68-3-4-19-24 EDN: https://elibrary.ru/BMKHKH
8. Sachs G., Shin J. M., Howden C.W. Review Article: The Clinical Pharmacology of Proton Pump Inhibitors. Aliment. Pharmacol. Ther., 2006, 23, 2−8. https://doi.org/10.1111/j.1365-2036.2006.02943.x
9. Gaba M., Singh S., Mohan C. Benzimidazole: An Emerging Scaffold for Analgesic and Anti-Inflammatory Agents. Eur. J. Med. Chem., 2014, 76, 494−505. https://doi.org/10.1016/j.ejmech.2014.01.030 EDN: https://elibrary.ru/WQYZRP
10. Michel M.C., Foster C., Brunner H.R., Liu L. A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists. Pharmacol. Rev., 2013, 65(2), 809−848. https://doi.org/10.1124/pr.112.007278 EDN: https://elibrary.ru/YEUTGB
11. Hamitova A.E., Berillo D.A. Obzor proizvodnyh piperidina i morfolina kak perspektivnye istochniki biologicheski aktivnyh soedineniy. RRLS, 2023, 12(2), 44–54. https://doi.org/10.33380/2305-2066-2023-12-2-44-54 EDN: https://elibrary.ru/PRSZWP
12. Kourounakis A.P., Xanthopoulos D., Tzara A. Morpholine as a privileged structure: a review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules. Med. Res. Rev., 2020, 40(2), 709–752. DOIhttps://doi.org/10.1002/med.21634 EDN: https://elibrary.ru/DEMMSN
13. Arshad F., Khan M.F., Akhtar W., Alam M.M., Nainwal L.M., Kaushik S. K., Akhter M., Parvez S., Hasan S.M., Shaquiquzzaman M. Revealing quinquennial anticancer journey of morpholine: A SAR based review. Eur. J. Med. Chem., 2019, 167, 324–356. DOI:https://doi.org/10.1016/j.ejmech.2019.02.015 EDN: https://elibrary.ru/ZVMYYV
14. Han C., Wirianto M., Kim E., Burish M.J., Yoo S. H., Chen Z. Clock-modulating activities of the anti-arrhythmic drug moricizine. Clocks & sleep, 2021, 3(3), 351–365. https://doi.org/10.3390/clockssleep3030022
15. Aziz M.N., Panda S.S., Shalaby E.M., Fawzy N.G., Girgis A.S. Facile synthetic approach towards vasorelaxant active 4-hydroxyquinazoline-4-carboxamides. RSC Advances, 2019, 9(49), 28534–28540. DOI:https://doi.org/10.1039/C9RA04321G.
16. Pourshojaei Y., Abiri A., Eskandari K., Haghighijoo Z., Edraki N., Asadipour A. Rhenoxyethyl piperidine/morpholine Derivatives as pAS and cAS inhibitors of cholinesterases: insights for future Drug Design. Sci. Rep., 2019, 9(1), 1–19. DOIhttps://doi.org/10.1038/s41598-019-56463-2.
17. Begunov R.S., Savina L.I., Astaf'eva D.A. Vnutrimolekulyarnoe aminirovanie orto-nitro-tret-anilinov kak odin iz putey sinteza kondensirovannyh proizvodnyh benzimidazola s uzlovym atomom azota. Ot himii k tehnologii shag za shagom, 2025, 6(1), 22-33. URL: https://chemintech.ru/ru/nauka/issue/5879/view (data obrascheniya 16.10.2025). DOI: https://doi.org/10.52957/2782-1900-2025-6-1-22-33; EDN: https://elibrary.ru/YUCJVL
18. Li Xin, Zeng Changgen, Dong Huaide, He Feng. Patent CN 116891484, 2023
19. Dubois L., Evanno Y., Even L., Gille C., Malanda A., Machnik D., Rakotoarisoa N. Patent US 8288376, 2012.
20. Huo X., Hou D., Wang H., He B., Fang J., Meng Y., Liu L., Wei Z., Wang Z., Liu F.W. Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives. Eur. J. Med. Chem., 2021, 224, 113684. DOI:https://doi.org/10.1016/j.ejmech.2021.113684. EDN: https://elibrary.ru/OZOQKN
21. Romero F.A., Kirschberg T.A., Halcomb R., XU Yingzi Patent US 10889571, 2021
22. Begunov R.S., Sokolov A.A., Belova V.O., Fakhrutdinov A.N., Shashkov A.S., Fedyanin I.V. Reaction of substituted pyrido[1,2-a]benzimidazoles with electrophilic agents. Tetrahedron Lett., 2015, 56(42), 5701-5704. DOI:https://doi.org/10.1016/j.tetlet.2015.08.014 EDN: https://elibrary.ru/UZZOTL
